Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,162,138
  • Shares Outstanding, K 20,342
  • Annual Sales, $ 98,430 K
  • Annual Income, $ -118,960 K
  • EBIT $ -138 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.27
  • Price/Sales 11.34
  • Price/Cash Flow N/A
  • Price/Book 12.26

Options Overview Details

View History
  • Implied Volatility 149.62% (-4.32%)
  • Historical Volatility 79.63%
  • IV Percentile 57%
  • IV Rank 16.35%
  • IV High 620.58% on 04/16/25
  • IV Low 57.54% on 12/10/24
  • Expected Move (DTE 14) 15.39 (26.67%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 775
  • Volume Avg (30-Day) 1,864
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 28,448
  • Open Int (30-Day) 39,082
  • Expected Range 42.31 to 73.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.69
  • Number of Estimates 6
  • High Estimate -1.98
  • Low Estimate -3.68
  • Prior Year -2.25
  • Growth Rate Est. (year over year) -19.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.50 +9.89%
on 11/14/25
66.86 -13.72%
on 11/28/25
+1.67 (+2.98%)
since 11/04/25
3-Month
34.62 +66.64%
on 09/05/25
66.92 -13.79%
on 10/31/25
+21.71 (+60.34%)
since 09/04/25
52-Week
6.45 +794.42%
on 04/09/25
66.92 -13.79%
on 10/31/25
+42.39 (+277.06%)
since 12/04/24

Most Recent Stories

More News
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma

NKTR : 57.69 (+0.98%)
Nektar: Q3 Earnings Snapshot

Nektar: Q3 Earnings Snapshot

NKTR : 57.69 (+0.98%)
Nektar Therapeutics Reports Third Quarter 2025 Financial Results

SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025.

NKTR : 57.69 (+0.98%)
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare...

NKTR : 57.69 (+0.98%)
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based...

NKTR : 57.69 (+0.98%)
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist...

NKTR : 57.69 (+0.98%)
BTIG Remains a Buy on Nektar Therapeutics (NKTR)

In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Nektar Therapeutics, with a price target of $100.00. The company’s shares closed yesterday at $58.85.Elevate Your...

NKTR : 57.69 (+0.98%)
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis

NKTR : 57.69 (+0.98%)
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025...

NKTR : 57.69 (+0.98%)
Nektar Therapeutics to Participate in Two Investor Conferences in September

SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27 th...

NKTR : 57.69 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 61.90
2nd Resistance Point 59.88
1st Resistance Point 58.78
Last Price 57.69
1st Support Level 55.67
2nd Support Level 53.65
3rd Support Level 52.55

See More

52-Week High 66.92
Last Price 57.69
Fibonacci 61.8% 43.82
Fibonacci 50% 36.68
Fibonacci 38.2% 29.55
52-Week Low 6.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar